Researchers at Stanford have created the first small primate model to study human heart rhythm disorders and also discovered a new way the heart keeps its beat.
Stanford scientists have discovered a novel approach to address cardiovascular complications resulting from cancer chemotherapy, particularly those caused by tyrosine kinase inhibitors (TKIs).
Stanford researchers have found that inhibiting 15-prostaglandin dehydrogenase (15-PGDH), which breaks down prostaglandin E2 (PGE2), can improve cardiac function in diseased and aged hearts.
Stanford researchers have developed an innovative, non-invasive therapeutic strategy to treat myocardial fibrosis (MF), a key driver of arrhythmia and heart failure in LMNA-related dilated cardiomyopathy (LMNA-DCM).
Heart failure is a complex cardiovascular disease that affects 26 million people worldwide and is characterized by the inability of the heart to pump blood effectively, leading to a decline in its normal functions.
Stanford researchers have developed a method of reducing pulmonary hypertension (PH) in mammals by targeting FHIT (Fragile Histidine Triad), a gene not previously linked to PH but consistently reduced in blood of patients with pulmonary arterial hypertension (PAH).
Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
Stanford inventors have developed a method to create spatially micropatterned vascularized structures that enable in vitro representation of human and animal biology in models such as cells, tissues, organs, and organoids.
Stanford researchers have patented a photosynthetic system using a cyanobacterium solution that can be delivered to ischemic tissues, where blood flow is insufficient. This addresses a major clinical problem for patients with heart and vascular diseases.